Maitri Patel, MD
Child & Adolescent Psychiatry · Framingham, MANPI 1912945213
Payments from drug & device makers
Across 792 payments — averaging $349.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$159K
- AbbVie$52K
- Collegium Pharmaceutical, Inc.$43K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Neuronetics, Inc.$2K
- Sunovion Pharmaceuticals Inc.$866
- plus $5K from 20 others
What the payments were for
- Consulting fees$24,4439%
- Speaking & faculty fees$191,90369%
- Travel & lodging$44,04216%
- Food & beverage$16,6076%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 394 | $159,397 |
| AbbVie(2 entities) | 138 | $52,004 |
| Collegium Pharmaceutical, Inc. | 59 | $42,943 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $14,577 |
| Neuronetics, Inc. | 2 | $2,154 |
| Sunovion Pharmaceuticals Inc. | 17 | $866 |
| Neos Therapeutics, LP | 39 | $824 |
| Johnson & Johnson | 7 | $743 |
| Neurocrine Biosciences, Inc. | 9 | $548 |
| Otsuka America Pharmaceutical, Inc. | 14 | $513 |
| Alkermes, Inc. | 10 | $480 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $448 |
| Lundbeck LLC | 18 | $352 |
| Supernus Pharmaceuticals, Inc. | 3 | $331 |
| E.r. Squibb & Sons, L.L.C. | 4 | $191 |
| Teva Pharmaceuticals USA, Inc. | 3 | $189 |
| Vanda Pharmaceuticals Inc. | 6 | $116 |
| Vertical Pharmaceuticals, LLC | 4 | $88 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $83 |
| Tris Pharma Inc | 4 | $69 |
| Corium, LLC | 4 | $53 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$190,252
- VRAYLAR$49,713
- VYVANSE$9,086
- TRINTELLIX$4,984
- Jornay PM 20mg capsules (Bottle of 100)$4,571
- NEUROSTAR TMS THERAPY SYSTEM$2,154
- ARISTADA$911
- INVEGA SUSTENNA$477
- SPRAVATO$377
- QELBREE$284
- ARISTADA INITIO$228
- INGREZZA$223
- INVEGA TRINZA$127
- INVEGA$127
- AUSTEDO$121
- REXULTI$120
- ABILIFY MAINTENA$113
- ABILIFY ASIMTUFII$113
- COBENFY$110
- CAPLYTA$101
How this compares
$277,107 in reported general payments places this provider in the 95th percentile of 104 child & adolescent psychiatry providers in Massachusetts.
See all child & adolescent psychiatry providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 13 | $297,793 |
| IngrezzaValbenazine Tosylate | 24 | $192,678 |
| VraylarCariprazine Hcl | 16 | $23,804 |
| Cotempla Xr-OdtMethylphenidate | 12 | $12,640 |
| TrintellixVortioxetine Hydrobromide | 14 | $10,635 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $7,225 |
| Lamotrigine | 25 | $1,281 |
| Clonidine Hcl ErClonidine Hcl | 13 | $977 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $742 |
| Sertraline Hcl | 44 | $649 |
| Mirtazapine | 12 | $437 |
| Buspirone Hcl | 11 | $363 |
| Clonazepam | 15 | $269 |
| Escitalopram Oxalate | 11 | $237 |
| Lurasidone Hcl | 15 | $177 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Hetlioz | $116 | $297,79313 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $548 | $192,67824 claims |
| AbbVieVraylar | $52,004 | $23,80416 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $14,577 | $17,86030 claims |
| Neos Therapeutics, LPCotempla Xr-Odt | $824 | $12,64012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 child & adolescent psychiatry providers in Massachusetts.
Other child & adolescent psychiatry in Framingham
- Sean MackintoshFramingham$630
- Kyle WilliamsBoston$327K
- Joseph BiedermanBoston$201K
- David DemasoBoston$41K
- Blaise AguirreBelmont$21K
- Matthew SiegelBoston$11K
- Janet WozniakBoston$8K
- Joseph Gonzalez HeydrichBoston$7K
- Michael MarcusBoston$4K
- Ranna ParekhBoston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.